证券代码：603087 证券简称：甘李药业 公告编号：2025-043 甘李药业股份有限公司 关于变更法定代表人并换发营业执照的公告 根据《公司章程》的规定，陈伟先生担任公司法定代表人。公司已于近日完 成了法定代表人变更的工商登记手续，并取得了北京市通州区市场监督管理局换 发的《营业执照》。公司新营业执照法定代表人变更为陈伟先生，原营业执照其 他登记事项未发生变更。 成立日期：1998 年 6 月 17 日 住所：北京市通州区漷县镇南风西一路 8 号 变更后的《营业执照》基本信息如下： 名称：甘李药业股份有限公司 统一社会信用代码：91110000102382249M 类型：股份有限公司（外商投资、上市） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 法定代表人：陈伟 甘李药业股份有限公司（以下简称"公司"）于 2025 年 5 月 20 日召开了 2024 年年度股东大会审议通过了《关于选举公司第五届董事会非独立董事的议 案》。5 月 30 日，公司召开第五届董事会第一次会议，审议通过了《关于公司 选举董事长的议案》，选举 ...

Investment Rating - The industry investment rating is "Overweight" (maintained) [5] Core Viewpoints - The report highlights the upcoming 85th Annual Scientific Sessions of the American Diabetes Association (ADA) from June 20-23, 2025, which is expected to showcase significant advancements in GLP-1 class drugs and weight management strategies [5][6] - The report emphasizes the increasing international recognition of China's innovations in the endocrine and metabolic fields, particularly in the GLP class drug sector, with notable achievements from companies like Innovent Biologics and Eli Lilly [7][8] - The report anticipates a substantial growth in China's GLP-1 weight loss drug market, projecting a market size exceeding 15 billion yuan by 2025, with penetration rates expected to rise from under 5% in 2023 to 18%-20% [8] Summary by Sections Recent Industry Performance - The industry has shown relative returns of 8.85% over the past month, 10.28% over the past three months, and 3.81% over the past year compared to the CSI 300 index [3] Investment Highlights - The report focuses on the catalysts from the ADA conference, particularly the advancements in GLP-1 class drugs, which are expected to drive investment opportunities [6][7] - Key companies mentioned include Eli Lilly, Novo Nordisk, and domestic firms like Boryung Pharmaceutical and Gan & Lee Pharmaceuticals, which are actively involved in GLP-1 drug development [7][8] Market Dynamics - The report notes the active business development transactions in the GLP class drug sector, indicating a high level of industry enthusiasm and potential for growth [7] - It also mentions the upcoming global diabetes-related conferences in 2025, which will further stimulate the market for GLP class drugs [8]

Group 1: Market Performance - The weight loss drug concept index rose by 1.46%, ranking 7th among concept sectors, with 27 stocks increasing in value [1] - Notable gainers included Zhongsheng Pharmaceutical, which hit the daily limit, and Hanyu Pharmaceutical, Yipinhong, and Tianenkang, with increases of 13.58%, 9.40%, and 9.35% respectively [1] - The sector experienced a net outflow of 600 million yuan in capital, with 23 stocks seeing net inflows, and 6 stocks receiving over 30 million yuan in net inflows [2] Group 2: Capital Flow - Leading the net inflow of capital was Lepu Medical, with a net inflow of 176 million yuan, followed by Hengrui Medicine and Ganli Pharmaceutical with net inflows of 164 million yuan and 117 million yuan respectively [2] - The top three stocks by net inflow ratio were Kexing Pharmaceutical, Lepu Medical, and Ganli Pharmaceutical, with net inflow ratios of 9.86%, 9.24%, and 8.74% respectively [3] Group 3: Stock Performance - The stock performance table indicated that Lepu Medical had a daily increase of 4.10% with a turnover rate of 8.77%, while Hengrui Medicine rose by 1.42% with a turnover rate of 0.75% [3] - Other notable performers included Tianenkang with a 9.35% increase and a turnover rate of 10.42%, and Kexing Pharmaceutical with a 6.40% increase and a turnover rate of 3.35% [4]

Investment Rating - Investment Rating: Buy (Maintain) [3] Core Views - The company reported a revenue of 3.045 billion yuan in 2024, representing a year-on-year growth of 16.77%, and a net profit attributable to shareholders of 615 million yuan, up 80.75% year-on-year, primarily due to significant gains from fair value changes of financial assets and disposal of financial assets [6][12] - In Q1 2025, the company achieved a revenue of 985 million yuan, a year-on-year increase of 75.76%, with a net profit of 312 million yuan, up 224.90% year-on-year [7][12] - The domestic insulin market is experiencing both volume and price increases, with domestic revenue in Q1 2025 reaching 889 million yuan, a growth of 80.07% year-on-year [8] - The company is expanding its overseas business, with overseas revenue in 2024 reaching 528 million yuan, a year-on-year increase of 23.89% [9] Financial Performance Summary - Revenue for 2025 is projected to be 4.393 billion yuan, with a year-on-year growth of 44.2%, and net profit is expected to reach 1.113 billion yuan, growing by 81.0% [12][14] - The company’s gross margin is expected to improve to 77.7% in 2025, with a return on equity (ROE) projected at 9.5% [14] - Earnings per share (EPS) for 2025 is estimated at 1.85 yuan, with a price-to-earnings (P/E) ratio of 30 times [12][14]

Core Viewpoint - The weight loss drug concept sector has seen a significant increase, with a rise of 4.66% as of June 9, positioning it as the second-highest gaining sector in the market [1]. Group 1: Market Performance - Within the weight loss drug sector, 48 stocks experienced gains, with Changshan Pharmaceutical reaching a 20% limit up [1]. - Notable gainers include Zhongsheng Pharmaceutical, Meinuo Pharmaceutical, and Shuanglu Pharmaceutical, all hitting the limit up, while Xinnoway and *ST Sansheng were among the few decliners [1]. - The sector's performance is reflected in the daily gainers and losers table, highlighting the overall positive trend in the weight loss drug concept [1]. Group 2: Capital Flow - The weight loss drug sector attracted a net inflow of 237 million yuan from major funds, with 27 stocks receiving net inflows [1]. - Zhongsheng Pharmaceutical led the net inflow with 247 million yuan, followed by Zhifei Biological, Shuanglu Pharmaceutical, and Ganli Pharmaceutical, which also saw significant inflows [1][2]. - The net inflow ratios for leading stocks in the sector were notably high, with Zhongsheng Pharmaceutical at 55.08%, indicating strong investor interest [2][3]. Group 3: Stock Performance Metrics - Key stocks in the weight loss drug sector showed impressive daily performance metrics, with Zhongsheng Pharmaceutical and Shuanglu Pharmaceutical both achieving nearly 10% gains [2][3]. - The turnover rates for these stocks also reflect active trading, with Zhongsheng Pharmaceutical at 3.84% and Shuanglu Pharmaceutical at 7.00% [2][3]. - The data indicates a robust interest in the weight loss drug sector, as evidenced by the high net inflow ratios and significant daily price movements [2][3].

Core Points - The company announced a cash dividend distribution of 1 yuan per share for its A shares, totaling approximately 597.53 million yuan (including tax) based on a total share capital of 601,065,290 shares, excluding 3,540,021 shares held in the repurchase account [1][2] - The dividend distribution plan was approved at the annual general meeting on May 20, 2025, and the key dates for the distribution are as follows: record date on June 10, 2025, last trading day on June 11, 2025, and ex-dividend date also on June 11, 2025 [1][2] - The company will not issue new shares or increase capital reserves, resulting in no change in the number of circulating shares, with a change ratio of "0" [2] Dividend Distribution Details - The cash dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the record date [1][2] - The actual cash dividend per share after tax for individual shareholders holding shares for more than one year will be 1 yuan, while for those holding shares for less than one month, the full amount will be subject to tax [4][6] - For qualified foreign institutional investors (QFII), the net cash dividend after a 10% withholding tax will be 0.90 yuan per share [5] Price Adjustment - Following the completion of the dividend distribution, the company will adjust the relevant prices associated with its equity incentive plans, with further details to be announced later [6]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/9/6 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2024 9 日~2025 9 4 | 5 | 年 | 月 | 日 | | 预计回购金额 | 15,000万元~30,000万元 | | | | | | 回购用途 | √减少注册资本 | | | | | | | □用于员工持股计划或股权激励 | | | | | | | □用于转换公司可转债 | | | | | | | □为维护公司价值及股东权益 | | | | | | 累计已回购股数 | 354.0021万股 | | | | | | 累计已回购股数占总股本比例 | 0.5890% | | | | | | 累计已回购金额 | 15,006.9654万元 | | | | | | 实际回购价格区间 | 37.65元/股~45.14元/股 | | | | | 一、 回购股份的基本情况 甘李药业股份有 ...

北京市中伦律师事务所 关于甘李药业股份有限公司 差异化分红事项的 法律意见书 二〇二五年五月 关于甘李药业股份有限公司 差异化分红事项的 法律意见书 致：甘李药业股份有限公司 北京市中伦律师事务所（以下简称"本所"）作为甘李药业股份有限公司（以 下简称"公司"）聘请的专项法律顾问，根据《中华人民共和国公司法》（以下简 称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公 司股份回购规则》（以下简称"《回购规则》"）、《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》（以下简称"《监管指引第 7 号》"）及《上海证券交 易所交易规则》等相关法律、行政法规、规章、规范性文件及《甘李药业股份有 限公司章程》（以下简称"《公司章程》"）的规定，按照律师行业公认的业务标准、 道德规范和勤勉尽责精神，对公司 2024 年度利润分配所涉及的差异化分红（以 下简称"本次差异化分红"）相关事项所涉及的有关事实进行核查的基础上，出 具本法律意见书。 就公司提供的文件、资料和陈述，本所及本所律师已得到公司的如下保证： 1．文件上所有的签名、印鉴都是真实的； 2．所有提供给本所及本所律师的文件 ...

甘李药业股份有限公司 证券代码：603087 证券简称：甘李药业 公告编号：2025-041 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放 | | --- | --- | --- | --- | --- | | | | | | 日 | | Ａ股 | 2025/6/10 | － | 2025/6/11 | 2025/6/11 | 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 20 日的2024年年度股东大会审议通过。 二、 分配方案 本次利润分配以实施权益分派股权登记日登记的公司总股本 601,065,290 股为 基数，扣除回购专用账户上的股份 3,540,021 股，即以 597,525,269 股为基数，向 全体股东每股派发现金红利 1 元（含税），共计派发现金红利 597,525,269 元(含税)。 根据公司 2024 年年度股东 ...

Core Viewpoint - The announcement details the achievement of conditions for the second unlock period of the 2022 restricted stock incentive plan of Ganli Pharmaceutical, allowing 125 eligible participants to unlock a total of 1,121,760 shares [1][9][12] Summary by Sections 1. Approval and Implementation of the Incentive Plan - The incentive plan was approved on October 24, 2022, during the fourth board meeting, with independent directors expressing agreement [2] - The list of incentive objects was disclosed on October 25, 2022, and no objections were raised during the public notice period [2] - The first extraordinary general meeting of shareholders approved the plan on November 15, 2022 [2] - Adjustments to the incentive object list were made on November 28, 2022, with independent directors and the supervisory board agreeing [3] 2. Conditions for Unlocking Shares - The second unlock period has been reached, with the unlock conditions specified in the incentive plan [4] - The second unlock period conditions include no negative audit opinions on financial reports and no disqualifications of incentive objects [5][6][7] - The company achieved a net profit of 6.15 billion for the 2024 fiscal year, exceeding the required 6 billion, thus meeting the performance criteria for the second unlock period [9] 3. Specifics of the Unlocking Process - A total of 112.176 million shares will be unlocked, representing 29.98% of the total granted shares [4][11] - The unlocking procedures will be completed after the 2024 profit distribution, with a subsequent announcement to investors [4] - The incentive plan allows for annual assessments of the incentive objects, determining the proportion of shares that can be unlocked based on individual performance [8][10] 4. Opinions from Committees - The Compensation and Assessment Committee confirmed that the conditions for the second unlock period have been met and that the 125 eligible participants are legally qualified [9] - The supervisory board also agreed that the conditions for unlocking shares are in compliance with relevant regulations and the incentive plan [10]